Drug intelligence / Profile preview

p946 + tet-p

Development stage: Unknown
Lead developer: National Cancer Institute
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

p946 + TET-P is an experimental combination vaccine therapy composed of two peptides—gp100[280-288] (referred to as p946) and a tetanus-derived peptide (TET-P)—used in the context of cancer immunotherapy. The combination is designed to stimulate the immune system against melanoma cells by presenting tumor-associated antigens (gp100) alongside a strong helper epitope from the tetanus toxin, which enhances immune response. This formulation has been studied with adjuvants such as QS-21 or IFA in clinical trials for metastatic melanoma[1][2].

Other names: gp100[280-288] peptide + tetanus peptide

Targets

pMHC-II (Peptide-major histocompatibility complex class II complex)PMEL (Melanocyte Protein PMEL)

Beyond the preview

Go deeper on p946 + tet-p.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on p946 + tet-p.

Explore the full profile